A botanical drug company in Brooklyn, New York

Brain medicine, grown from the whole plant.

Remedi Therapeutix is developing standardized botanical drugs from rare, varin-rich cannabinoids: CBDV, CBGV and CBG. We grow them in living soil, concentrate them without solvents, and are preparing the studies the FDA’s botanical drug pathway requires.

See the pipeline Partner or invest

Macro photograph of a cannabis trichome with its resin head — Trichome heads hold the plant’s cannabinoids

Path to approval

The FDA botanical drug pathway, and where Remedi stands today.

CultivarsCBG- and CBDV-rich lines grown and independently tested
LicensingNew York research license application under way
Phase 0Preclinical brain-delivery and seizure-model studies
Pre-INDFirst FDA meeting and orphan designation request
INDSafety studies and the IND filing
Phase 1First studies in people, after FDA clearance
Phase 2Proof of concept in the target condition

3.4 millionAmericans living with active epilepsy

About 30%of people with epilepsy have seizures that current medicines do not control

4botanical drugs approved by the FDA to date

Plant medicine has to meet the same standard as any drug.

Many families already look to cannabis when medicines fall short. What they can buy varies from jar to jar, and none of it has been through controlled trials.

The FDA’s botanical drug pathway is the way through. It reviews a whole-plant medicine as a complex mixture, without requiring one isolated molecule, as long as every batch is consistent and the trials succeed. Remedi is built around that standard, starting with the plant itself.

Sources: CDC (2015 data); Epilepsy Currents, 2018; FDA.

From seed to study, under one chain of custody.

Grow

Rare-cannabinoid cultivars bred and grown in living organic soil at Royal Crown Farm.

Concentrate

HALO extraction concentrates the whole plant in one step, with no solvents, water or ice.

Formulate

Computational models help choose cannabinoid and terpene ratios for specific brain targets.

Validate

Independent preclinical studies measure brain delivery and target engagement before any human study.

How the platform works

Pipeline

Four programs built on our CBDV-, CBGV- and CBG-rich cultivars. All are at the discovery stage; none has been tested in people.

Led by CBDVLed by CBG

Program

DiscoveryPreclinicalIND-enablingPhase 1Phase 2Phase 3

Targets and timelines may change as research progresses. Remedi Oil 001 is an investigational formulation: it is not for sale, has not been evaluated by the FDA and is not available to patients.

Program details

The botanical drug pathway

A botanical drug is a medicine made from plant material rather than one purified molecule. The FDA has approved four.

To join them, a product must be consistent from batch to batch, which starts with controlled genetics and growing conditions, and it must succeed in the same phased trials as any new drug. For rare conditions, orphan drug designation can support the work.

Source: FDA, What is a botanical drug?

Cultivars and testingCBG- and CBDV-rich cultivars grown in living soil, with independent certificates of analysis.
Research licensingNew York cannabis research license, then DEA registration.
Consistency (CMC)Locked cultivars, three consistent HALO batches and validated test methods.
Phase 0 preclinical studiesBrain delivery, target engagement and established seizure models.
Pre-IND meetingFirst formal meeting with the FDA, and an orphan drug designation request.
IND filingSafety (GLP toxicology) studies, then the Investigational New Drug application.
Clinical trialsPhase 1 safety, then Phase 2 proof of concept, only after FDA clearance.

One plant, one chain of custody.

Remedi works within a family of companies and research partners. Each does one part of the work, so every batch we study can be traced from seed to result.

Cultivation and extraction

Royal Crown Farm

Breeds and grows the CBG- and CBDV-rich cultivars in living organic soil.

Genetics, flower and extracts; cryosift license

Drug development

Remedi Therapeutix

Turns that material into standardized formulations and runs the studies.

Formulations for study

Research

Research partners

An academic laboratory for Phase 0, and pharma partners as programs advance.

Extraction technology: HALO is patented by Dynamicann Technologies and used by Remedi under license.
Independent testing: MCR Labs tests each cultivar batch by batch, and the certificates follow the material from farm to study.

Meet our partners

Partners

Cultivation, extraction and technology

Royal Crown Farm

Remedi’s sister company and source of every plant we study.

Breeds and grows CBG White 5, TKCBG 1, CBDV 3 and Key Lime CBG 2 in living organic soil
Supplies flower and extracts to Remedi
Licenses the cryosift process to Remedi

royalcrownfarm.com

Extraction technology

Dynamicann Technologies

Holds the patent for HALO, the one-step solventless process that concentrates the whole plant with no solvents, water or ice. Remedi uses HALO under license.

How HALO works

Independent testing

MCR Labs

Tests each cultivar batch by batch. Certificates of analysis are shared with research partners under a mutual NDA.

See the certificates

Preclinical research

Academic laboratory partner

Co-designing the Phase 0 studies: brain delivery, target engagement and seizure models. We will name our partner once the agreement is signed.

The Phase 0 plan

Open to new partners

Work with us

Pharma and biotech co-development
Clinical investigators and research institutions
Contract research and manufacturing organizations

Start a conversation

Why Remedi

We grow what we study

Every batch traces back to its cultivar, its bed and its harvest. That control is what the FDA asks a botanical drug to prove.

Varins are our focus

CBDV and CBGV are rare in most cannabis. Our cultivars are bred for them, and independent certificates confirm the levels.

Solventless by design

HALO concentrates the whole plant in one step, keeping the lipids and terpenes that ice-water methods wash away.

Built for the botanical pathway

Our process is designed around batch-to-batch consistency from the start, not added after a product exists.

Co-founders Frank Lopa and Tracey Lopa standing together outdoors

Why we started

Remedi began with one family’s search for something better. Tracey, Frank and Dr. Abe tell the story in their own words in The House of Jóia.

Read our story

Investors

Remedi is a preclinical company building toward an IND for a standardized, whole-plant botanical drug. We share our full briefing with accredited investors under a mutual NDA.

What we are building

Botanical drugs from varin-rich cultivars, CBDV first
A seed-to-study supply chain with Royal Crown Farm
Solventless HALO (licensed from Dynamicann) and cryosift (licensed from Royal Crown Farm)

Milestones ahead

New York research license and DEA registration
Phase 0 preclinical data
Pre-IND meeting with the FDA
Orphan drug designation request
IND clearance

Shared under NDA

Company briefing and use of funds
Full certificates of analysis
HALO process data
Program detail and study budgets

Request the briefing See the path to approval

Investor materials are provided only to accredited investors. Nothing on this site is an offer to sell or a solicitation of an offer to buy securities.

News

October 2026

Our founders’ stories featured in The House of Jóia

“Formulating the Impossible,” by Dr. Abraham Benavides, tells how Tracey, Frank and Dr. Abe came to found Remedi. Read the feature

August 2026

Independent certificates of analysis for three cultivars

MCR Labs tested CBG White 5, TKCBG 1 and CBDV 3 between August 28 and 31, 2026. See the certificates

Get updates

News on our research and milestones, a few times a year.

Close-up of a frosted, trichome-covered Royal Crown Farms flower on black

The House of Jóia · Issue 01 · October 2026 JÓIA Formulating the Impossible By Dr. Abraham Benavides, MD

Featured in The House of Jóia

Formulating the Impossible

A first-person feature by Dr. Abraham Benavides, MD · 22 pages

Love, landrace genetics and the next generation of cannabinoid research: the stories of the three people behind Remedi Therapeutix, told in their own words.

Read the full issue → Start with Tracey’s story

“It dulled everything.”Tracey Lopa, co-founder, on her years of medication

Chapter 01 · Tracey Lopa, co-founder

From refractory epilepsy to the reason Remedi exists.

In 2006 Tracey Lopa was diagnosed with unexplained, refractory epilepsy. For fourteen years she took the medicines she was prescribed, levetiracetam (Keppra®) and lamotrigine (Lamictal®). They held back her major seizures, but the fog they brought made it hard to be present with her children.

Her husband, Frank, went looking for another way. He sourced rare CBG White genetics from an organic farm in Ohio, grew the plants in living soil and developed a cryosift technique to make custom 52 mg CBGA sift capsules. Under her doctors’ supervision, Tracey gradually tapered off lamotrigine. Within three months she was seizure-controlled, which surprised her specialists and her father, an internist.

The next chapter came when Frank found and cultivated high-CBDV hemp. In Tracey’s experience, inhaled CBDV flower or vaporized concentrate stopped her seizure auras within a minute or two, and it brought balance to her mood, anxiety and stress.

Today Tracey has been seizure-free for more than six years. She drives again, travels, and is present for every moment with her family. Her experience is why she and Frank founded Remedi: to find out, with real science, whether what happened for her can be understood, measured and made available to others.

2006Diagnosed with refractory epilepsy

14 yrsOn Keppra® and Lamictal®

3 mosTo seizure control on CBG White

6+ yrsSeizure-free today

Frank Lopa and team in lab coats and shoe covers inside a cultivation facility

“We don’t cultivate cannabis. We cultivate people.”Frank Lopa, co-founder

Chapter 02 · Frank Lopa, co-founder

Three decades of genetics and solventless craft.

Frank Lopa has spent more than thirty years in cultivation, landrace genetics and solventless extraction. Through Royal Crown Farms, he and his family have self-funded decades of work preserving rare cultivars and growing them in living organic soil, in conditions that mirror each plant’s native home.

His focus on high-CBDV and rare-cannabinoid hemp is personal too. Frank is extremely sensitive to THC and lives with chronic Lyme disease and inflammation, so he needed plants that offered relief without intoxication. That led to a hemp program grown to the standard of connoisseur flower, in aroma, flavor and structure.

To keep the whole plant intact, Frank built two processes of his own:

A HALO cartridge filled with golden solventless extract

HALO extract

A one-step, whole-plant short-path process with no solvents, water or ice, in development since 2013. It concentrates native terpenes and plant lipids up to 20×.

Three Royal Crown Farms landrace cultivars in full flower

Cryosift

Pure trichome-head separations that yield high-potency CBG and CBDV sifts.

Dr. Abraham Benavides, MD, in a lab coat with a HALO cartridge and sample jar

“CBDV doesn’t get you high, but it adds joy, like feeling the beat drop in your favorite song.”Dr. Abraham Benavides, MD

Chapter 03 · Dr. Abraham Benavides, MD

The golden ticket.

In his own words · Executive R&D and Clinical Director

I have evaluated top-shelf cannabis in four countries and a dozen U.S. states. When Frank called with unusual lab results and an invitation, I flew from Costa Rica to Staten Island for a two-week research visit. On arrival he handed me a single serving of CBG HALO oil. Within about three minutes I felt deeply relaxed, and that night I slept without my usual nightmares or jet lag. It felt like Charlie finding the golden ticket.

For five years I have lived with Long COVID, POTS and PTSD. Inhaling Royal Crown Farms’ whole-plant CBDV flower (es el cannabis del cielo) eased my flashbacks, intrusive thoughts, hypervigilance and racing heart, and left my mind clear for work, without the dry mouth, fog or side effects I know from THC.

When I went home, my symptoms came back. That is why I joined Remedi: what I felt in New York deserves rigorous study, and patients deserve to know whether it holds up.

Chapter 04 · The lab speaks

Independent certificates of analysis.

The cultivars behind these stories, tested by MCR Labs. Full certificates are shared under a mutual NDA.

See HALO lab data →

CBG White 5CBGa 11.70% · CBG 0.80% · total cannabinoids 13.7% · max THC 0.18%

TKCBG 1CBDv 4.80% · CBGa 3.70% · total cannabinoids 9.8% · max THC 0.09%

CBDV 3CBDa 5.80% · CBDVa 3.30% · total cannabinoids 10.5% · max THC 0.26%

Films

Watch the work.

Short films from the people, the soil and the lab behind Remedi.

The Remedi platform

From soil to study, under one roof.

We control each step that shapes the oil, so every batch we study can be traced back to the plant it came from.

1. Grow

Living soil cultivation

Rare-cannabinoid cultivars grown at Royal Crown Farms in living organic soil, with no pesticides or chemicals.

2. Concentrate

HALO extraction

Vacuum short-path extraction that concentrates the whole plant with no solvents, water or ice.

3. Formulate

AI ratio modeling

Computational models help choose cannabinoid and terpene ratios aimed at specific brain targets.

4. Validate

Preclinical study

Independent laboratory work to measure brain delivery and target engagement before any human study.

HALO vs. rosin

Truly solventless. No ice. No water.

Common method

Ice-water hash and rosin

Trichomes are washed in ice and water
Plant lipids and waxes wash away with the water
Wash, dry, then press: several steps

Remedi

HALO

Proprietary vacuum short-path extraction
No solvents, no water, no ice
Keeps the plant’s lipids, waxes and terpenes
One step, flower to oil

Lab data

Measured, not modeled.

The same flower, tested before and after HALO by an independent laboratory.

16.4×total terpenes, Lucy Lavender (0.49% → 8.05%)

20.4×β-caryophyllene, identical in both HALO runs

41.5×peak single compound, terpinolene

Compound (run)	Flower %	HALO %	Gain

Source: MCR Labs, 03/03/2020. Same flower before and after HALO. Cannabinoids decarb-adjusted (acid × 0.877). LL = Lucy Lavender. Concentration data only; it does not show any health effect.

Royal Crown Farms

Rare cannabinoids, grown for medicine.

CBG- and CBDV-rich cultivars are growing today in Royal Crown Farms’ living organic soil, using Korean regenerative farming methods.

CBG White 5TKCBG 1CBDV 3Key Lime CBG 2

No pesticides and no chemicals. Each cultivar is tested batch by batch, and those certificates of analysis are shared with research partners.

Research

Phase 0: the first study.

A preclinical study plan, designed with an academic laboratory partner, to measure what our formulations do before anyone takes them.

Research in preparation

Study 1

Brain delivery

Pharmacokinetic study in rodents, measured by LC-MS/MS, comparing how much of each compound reaches the brain against a standard carrier oil.

Study 2

Target engagement

Laboratory assays at receptors and pathways linked to brain activity and inflammation, including TRPV1, GABA-A and IL-1β.

Study 3

Established seizure models

Standard preclinical models (PTZ or MES) that measure seizure latency, duration and threshold.

Study 4

Biomarkers and behavior

Gene-expression markers and recovery measures that show what changes, and what doesn’t, after treatment.

Phase 0

Prove brain delivery

Rodent PK study, first formulation tested, patent filings, CNS advisory team.

Phase 1

Build the platform

Central cultivation and extraction, assay setup, HALO scale-up.

Phase 2

Validate and partner

Pharma co-development and IND-enabling work on lead compounds.

Phase 3

Clinical trials

Only after FDA review: Phase 1 trials and GMP-grade production.

Voices

In their words.

Stories from founders, families and research partners, shared with written consent.

Reserved for a research partner or family story, added once written consent is on file.

Testimonial slot, text or video

Team

The founding team.

Each of us came to this work through a personal story. Read them in full in Formulating the Impossible.

Tracey Lopa

Co-founder

Diagnosed with refractory epilepsy in 2006, Tracey is the reason Remedi exists and its most important voice for patients and families.

Tracey’s story →

Frank Lopa

Co-founder

Thirty years in landrace genetics and living-soil cultivation through Royal Crown Farms; inventor of HALO extraction and Remedi’s cryosift process.

Frank’s story →

Dr. Abraham Benavides, MD

Executive R&D and Clinical Director

Clinician-scientist who leads research and clinical direction, and author of “Formulating the Impossible” in The House of Jóia.

Dr. Abe’s story →

The Priya Naturals team meeting at their trade-show booth — The Priya Naturals team on the trade-show floor.

Careers

Now building the leadership team.

Advisory or board seats are a good first step for each of these roles.

Open role

Chief Scientific Officer

Own Phase 0 design and execution, the CNS advisory board and the path from preclinical data to IND.

Express interest →

Open role

Chief Technology Officer

Own HALO scale-up on CBG and CBDV cultivars, a validated GMP-ready process and the formulation engine.

Express interest →

Open role

Chief Financial Officer

Own the company’s financing strategy, with experience in biotech finance and capital markets.

Express interest →

Investors & partners

Help build the next chapter of brain medicine.

Start with a 20-minute call. We share our full briefing, certificates of analysis and process data under a mutual NDA.

Dr. Abraham Benavides, MD

Executive R&D and Clinical Director

partners@remeditherapeutix.com

332.213.7393

Remedi Therapeutix · PO Box 82, Brooklyn, NY 11222

Investors & partners

Help build the next chapter of brain medicine.

Start with a 20-minute call. Our full briefing is shared under a mutual NDA.

Partner or invest

Page not found

This page isn’t here.

The link may be old or mistyped. Our pipeline, platform and partners are one click away.

Home See the pipeline Contact us